<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04828174</url>
  </required_header>
  <id_info>
    <org_study_id>SHYSXY-202101-CART</org_study_id>
    <nct_id>NCT04828174</nct_id>
  </id_info>
  <brief_title>Anti-TRBC1 CAR-T Cell Therapy in Patients With TRBC1 Positive T Cell Malignancies</brief_title>
  <official_title>The Safety and Clinical Efficacy of Human TRBC1 CAR-T Cell Therapy for Patients With Relapsed/Refractory TRBC1 Positive T Cell Hematological Maliganacies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of CAR T cell treatment&#xD;
      targeting TRBC1 in patients with relapsed or refractory TRBC1 positive T-cell hematological&#xD;
      maliganacies&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 31, 2021</start_date>
  <completion_date type="Anticipated">March 2024</completion_date>
  <primary_completion_date type="Anticipated">March 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Tolerability</measure>
    <time_frame>28 days post infusion</time_frame>
    <description>Safety measured by occurence of study related adverse effects defined by NCI CTCAE5.0</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CAR-T cell expansion and persistence</measure>
    <time_frame>2 years post infusion</time_frame>
    <description>To evaluate anti-TRBC1 CAR-T cell expansion and persistence after infusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total response rate (ORR) after administration</measure>
    <time_frame>3 months post infusion</time_frame>
    <description>CR+CRi for T-ALL CR+PR for T cell lyphoma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of remission (DOR) after administration</measure>
    <time_frame>2 years post infusion</time_frame>
    <description>Duration of remission (DOR) after administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)after administration</measure>
    <time_frame>2 years post infusion</time_frame>
    <description>Overall Survival (OS)after administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS) after infusion</measure>
    <time_frame>2 years after infusion</time_frame>
    <description>Progression Free Survival (PFS) after infusion</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">9</enrollment>
  <condition>Peripheral T Cell Lymphoma</condition>
  <condition>Angioimmunoblastic T-cell Lymphoma</condition>
  <condition>Anaplastic Lymphoma</condition>
  <condition>Acute T Cell Leukemia</condition>
  <condition>T-lymphoblastic Lymphoma</condition>
  <arm_group>
    <arm_group_label>anti-TRBC1 CAR-T cell</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration with anti-TRBC1 CAR-T cells in the relapsed/refractory T cell hematological malignancy patients.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>anti-TRBC1 CAR-T cell therapy</intervention_name>
    <description>TRBC1 positve patients with relapsed or refractory T cell malignacy will receive CAR-T cell therapy targetting TRBC1</description>
    <arm_group_label>anti-TRBC1 CAR-T cell</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        (1)18 to 70 Years Old, Male and female; (2) Expected survival &gt; 12 weeks; (3) ECOG score&#xD;
        0-2; (4) Confirmed diagnosis of acute T cell leukemia and screened for TRBC1 positive,&#xD;
        including following conditions:&#xD;
&#xD;
          1. Patients who do not get a CR with ≥2 prior lines of therapy&#xD;
&#xD;
          2. Those who achieves CR, but have a early relapse(&lt;12months),or a late relapse&#xD;
             (&gt;=12months) failing to acheive a CR after 1 line salvage chemotherapy&#xD;
&#xD;
          3. For any Patiens failed ASCT/allo-SCT (5) Relapsed and refractory patients with&#xD;
             diagnosis of T cell lymphoma have had≥2 prior lines of therapy,including:&#xD;
&#xD;
        a. Peripheral T cell lymphoma NOS, or b. Angioimmunoblastic T cell lymphoma, or c.&#xD;
        Anaplastic large cell lymphoma (6) Confirmed T lymphoblatic lymphoma&#xD;
&#xD;
          1. Patients who do not get a CR with ≥2 prior lines of therapy&#xD;
&#xD;
          2. Relapsed patients failing to acheive a CR after 1 line salvage chemotherapy&#xD;
&#xD;
          3. For any Patiens failed ASCT/allo-SCT (7) The venous access required for collection can&#xD;
             be established and mononuclear cell collection can be determined by the investigators;&#xD;
             (8) Liver, kidney and cardiopulmonary functions meet the following requirements:&#xD;
&#xD;
        a. Ccr≥60mL/min(Cockcroft Gault) b. Left ventricular ejection fraction &gt;50%; c. Baseline&#xD;
        oxygen saturation&gt;92%; d. Total bilirubin ≤ 1.5×ULN; e. ALT and AST ≤ 3×ULN; (9) Able to&#xD;
        understand and sign the In&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Malignant tumors other than acute lymphoblastic leukemia within 5 years prior to&#xD;
             screening, in addition to adequately treated cervical carcinoma in situ, basal cell or&#xD;
             squamous cell skin cancer, localized prostate cancer after radical resection, and&#xD;
             ductal carcinoma in situ after radical resection;&#xD;
&#xD;
          2. Uncontrolled infection;patients with positive HBsAg or HBcAb and peripheral blood HBV&#xD;
             DNA titer detection ≥ 1 × 10^2 copy number / L; HCV antibody positive and peripheral&#xD;
             blood HCV RNA positive; HIV antibody positive; CMV DNA positive; syphilis positive;&#xD;
&#xD;
          3. Any instability of systemic disease, including but not limited to unstable angina,&#xD;
             cerebrovascular accident, or transient cerebral ischemic (within 6 months prior to&#xD;
             screening), myocardial infarction (within 6 months prior to screening), congestive&#xD;
             heart failure (New York heart association (NYHA) classification ≥ III), need drug&#xD;
             therapy of severe arrhythmia, liver, kidney, or metabolic disease;&#xD;
&#xD;
          4. Any uncontrolled disease may affect entry&#xD;
&#xD;
          5. Current or history of CNS involvement by malignancy.Known history or presence of&#xD;
             clinically relevant central nervous system (CNS) pathology. Patients with a known&#xD;
             history or prior diagnosis other immunologic or inflammatory disease affecting the CNS&#xD;
             (such as epilepsy)&#xD;
&#xD;
          6. Patients who are receiving systemic steroid treatment and requiring long-term systemic&#xD;
             steroid treatment during the treatment as determined by the investigator before&#xD;
             screening (except inhalation or topical use); And subjects treated with systemic&#xD;
             steroids (except inhalation or topical use) within 72h prior to cell transfusion;&#xD;
&#xD;
          7. Pregnant or lactating woman, and female subject who plans to have a pregnancy within 1&#xD;
             year after cell transfusion, or male subject whose partner plans to have a pr egnancy&#xD;
             within 1 year after cell transfusion;&#xD;
&#xD;
          8. Active or uncontrollable infection requiring systemic therapy&#xD;
&#xD;
          9. Received CAR-T treatment or other gene therapies before enrollment;&#xD;
&#xD;
         10. Kown be allergic to anti-TRBC1 CAR-T cells or drugs(Fludarabine or Cyclophophamide)&#xD;
&#xD;
         11. The investigators consider other conditions unsuitable for enrollment.&#xD;
&#xD;
         12. Patients who may not be able to sign the Informed Consent due to disease,or who do not&#xD;
             understand or unwillingness or inability to comply with research requirements&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Xianmin Song</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200080</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xianmin Song, MD</last_name>
      <phone>021-63240090</phone>
      <email>shongxm@139.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 31, 2021</study_first_submitted>
  <study_first_submitted_qc>March 31, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 1, 2021</study_first_posted>
  <last_update_submitted>March 31, 2021</last_update_submitted>
  <last_update_submitted_qc>March 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine</investigator_affiliation>
    <investigator_full_name>Xianmin Song, MD</investigator_full_name>
    <investigator_title>principal investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, T-Cell</mesh_term>
    <mesh_term>Lymphoma, T-Cell, Peripheral</mesh_term>
    <mesh_term>Precursor T-Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Immunoblastic Lymphadenopathy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

